30392-40-6

Basic information

• Product Name: Bitolterol
• Synonyms: Bis(4-methylbenzoic acid)4-[2-(tert-butylamino)-1-hydroxyethyl]-1,2-phenylene ester;Bis(p-toluic acid)4-[2-(tert-butylamino)-1-hydroxyethyl]-1,2-phenylene ester;C06853
• CAS NO: 30392-40-6
• Molecular Formula: C28H31NO5
• Molecular Weight: 461.55
• Product Categories: Aromatics, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 30392-40-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 640.5°C at 760 mmHg
• Flash Point: 341.2°C
• Appearance: /
• Density: 1.169g/cm³
• Vapor Pressure: 2.77E-17mmHg at 25°C
• Refractive Index: 1.585
• PKA: 13.61±0.20(Predicted)
• CAS DataBase Reference: Bitolterol(CAS DataBase Reference)
• NIST Chemistry Reference: Bitolterol(30392-40-6)
• EPA Substance Registry System: Bitolterol(30392-40-6)

Safety Data

• Hazardous Substances Data: 30392-40-6(Hazardous Substances Data)

Usage

Description

Bitolterol, a β2-adrenergic receptor agonist, is a medication primarily utilized in the treatment of respiratory conditions. It functions by stimulating the β2-adrenergic receptors in the lungs, leading to the relaxation of bronchial muscles and dilation of airways. This action results in the alleviation of bronchospasm, making it a valuable asset in managing asthma and chronic obstructive pulmonary disease (COPD).
Source:
Bitolterol is synthesized through a series of chemical reactions and is derived from the adrenergic drug class.
Production Methods:
The production of Bitolterol involves a series of chemical processes that transform its precursor compounds into the active pharmaceutical ingredient. These processes are carefully controlled to ensure the purity and potency of the final product.

Uses

Used in Pharmaceutical Industry:
Bitolterol is used as a bronchodilator for the relief of bronchospasm in patients suffering from asthma and chronic obstructive pulmonary disease (COPD). Its ability to stimulate β2-adrenergic receptors in the lungs promotes the relaxation of bronchial muscles and dilation of airways, providing significant relief from respiratory distress.
Brand Name:
Bitolterol is marketed under the brand name Tornalate by Sanofi Aventis, a global pharmaceutical company. This brand name is recognized for its effectiveness in treating respiratory conditions and improving the quality of life for patients with asthma and COPD.

InChI:InChI=1/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3

Downstream Products

• 47793-57-7 C₃₀H₃₃NO₆ 

Relevant articles and documents

Combined doses

The present invention discloses a method and a pharmaceutical dry powder combined dose for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders. At least one dry powder medicament is selected from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments. A metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments is prepared, in which the sum of the metered deposits constitutes the metered quantities of powder of the combined dose and the medicinal combined dose is introduced into an adapted inhaler device for a generally simultaneous delivery of the medicinal combined dose during the course of a single inhalation by a user, such that the delivered medicinal combined dose is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments, whereby an desired therapeutic or treating effect to the user is achieved.